Who should get genetic testing for cardiac channelopathies?

The yield is low, the tests are expensive and reimbursement policies are inconsistent. A recent paper looked at the yield and costs in different patient populations:

Conclusions— Genotyping can be performed at reasonable cost in individuals with conclusive diagnosis of long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia, and in patients with type I Brugada syndrome ECG with atrioventricular block. These patients should be given priority to access genetic testing.